If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue.Vera Therapeutics (VERA +13.25%) was a standout in the biotech sector on Wednesday. Its stock closed that trading session 13% higher, thanks in no small part to a bullish new note published by an analyst that morning. A huge potential marketThe prognosticator behind the positive note was Cantor Fitzgerald's Pete Stavropoulos, who reiterated his existing overweight (read: buy) recommendation and $1 ...

Annual General Meeting 2025 (ASX:IMM, NASDAQ:IMMP) 1 Empowering the immune system to fight cancer and autoimmune disease For personal use only Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should ...

These are historic days for the company, following its first FDA approval.The stock of biotech Arrowhead Pharmaceuticals (ARWR +23.34%) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release. A flying arrowThe previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of lice ...

Company Highlights - Zynex, Inc. (NASDAQ:ZYXI) experienced a 98% increase in stock price, reaching $1.46 from a low of $0.695, with a trading volume exceeding 66 million shares, driven by strong Q3 results [1][6] - Pasithea Therapeutics Corp. (KTTA) saw a 69.4% rise in stock price to $0.826, peaking at $1.34 during the day, with a trading volume of approximately 124 million shares, following a $1 million grant from the ALS Association for ALS research [2][6] - Amber International Holding Ltd (Nasdaq: AMBR) reported a 59.49% jump in stock price to $2.52, with over 85 million shares traded, and announced a $50 million share repurchase program, reflecting strong business momentum [3][6] - SMX (NASDAQ:SMX) saw its stock price climb by 58.21% to $9.35, with over 12 million shares traded, showcasing strong momentum at the 2025 DMCC Precious Metals Conference [4][6] Market Trends - The market is characterized by significant investor interest and stock price volatility across various sectors, including healthcare, biotechnology, real estate, and technology, driven by company-specific developments and broader market trends [5]

Core Insights - Neurizon Therapeutics Limited has appointed Ms. Justine Conway as a Board Observer, representing Elanco Animal Health, highlighting the strong partnership between the two companies [1][2][5] Group 1: Appointment and Role - Ms. Justine Conway is the Global Head of Business Development at Elanco and will participate in Neurizon's Board activities as Elanco's designated representative [1][3] - As a Board Observer, Ms. Conway will attend all Board and committee meetings but will not have voting rights [5] Group 2: Strategic Importance - The appointment underscores the strength of Neurizon's relationship with Elanco, particularly following an exclusive global license agreement for Monepantel, which is crucial for Neurizon's regulatory foundations and future clinical trials [2][6] - Neurizon aims to advance its lead drug candidate, NUZ-001, towards late-stage development and global commercialization, with Ms. Conway's expertise expected to support this process [5][6] Group 3: Ms. Conway's Background - Ms. Conway has over two decades of experience in the healthcare and animal health industries, including significant roles in investment banking at Macquarie Bank and Bank of America Merrill Lynch [3][4] - Her expertise includes executing M&A transactions and capital raisings, as well as leading major business development initiatives [4]

Core Points - Transgene successfully raised approximately €105 million through a fundraising initiative involving private placements and retail offerings at a price of €1.02 per share [1][6][10] - The funds will primarily support the development of the myvac® platform, which focuses on individualized therapeutic vaccines for cancer treatment [4][5][7] - The fundraising included participation from specialized healthcare investors and existing shareholders, indicating strong institutional interest [2][21] Fundraising Details - The fundraising consisted of a private placement and a public offering via the PrimaryBid platform, with a total of 141,433,349 new ordinary shares issued, representing 106.5% of the company's current share capital [9][10] - The subscription price of €1.02 per share reflects a 25% discount compared to the closing price prior to the fundraising [10] - A reserved capital increase of €39,262,015.44 was also conducted for TSGH, utilizing amounts advanced under a current account advance agreement [3][12] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing Phase 2 trials and the launch of new indications [7][5] - About 20% will be directed towards R&D costs related to the myvac® program and other clinical trials [7] - The remaining funds will cover general administrative expenses and recurring cash consumption [7] Expected Milestones - Key milestones include the completion of the ongoing Phase 2 trial in head and neck cancers, with results anticipated by late 2027 or early 2028 [4][15] - The company plans to launch a Phase 1 trial in a new indication and prepare for pivotal trials by the end of 2027 [15][4] Share Capital and Ownership Structure - Post-fundraising, the company's share capital will amount to €82,256,012.70, divided into 274,186,709 ordinary shares [18] - TSGH will hold 78.29% of the capital, while SITAM Belgium will hold 3.55%, with other shareholders comprising 18.16% [18][21] Trading and Regulatory Information - Trading of Transgene's shares on Euronext Paris was suspended during the fundraising and is set to resume on November 27, 2025 [23][24] - The new shares will be fungible with existing shares and will carry the same rights [25]

Core Insights - Hemostemix Inc. has initiated its strategy to acquire cardiology practices, starting with two prominent cardiologists in the Dominican Republic, Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, for 2,000,000 shares each [1][11] - The long-term strategy aims to integrate profitable medical practices to enhance the commercialization of ACP-01 treatments, creating a sustainable patient flow for the company [2][6] - The two cardiologists have extensive experience, having treated over 200 patients with ACP-01, positioning them as key figures in the company's expansion efforts [3][7] Company Strategy - The acquisition of these practices is part of a broader plan to establish a clinical and commercial presence internationally, with a focus on patient treatment flow and increasing practitioner engagement [2][6] - Hemostemix aims to replicate its business model across various markets, including Florida, Puerto Rico, and Canada, leveraging the expertise of the acquired cardiologists [6][7] Clinical Expertise - Dr. Fernandez-de-Castro and Dr. Figueroa will contribute their expertise in treating various cardiovascular conditions, including Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, and Vascular Dementia [5][4] - Their established reputations and patient bases in the Dominican Republic are expected to facilitate the implementation of ACP-01 therapy [4][5] Financial Aspects - The TSXV has approved an extension for a non-brokered private placement, allowing Hemostemix to raise funds at $0.11 per unit, with total gross proceeds of $461,230 raised to date [8] - Each unit consists of one common share and one warrant, with the potential for additional shares to be acquired at $0.15 per share [8] Company Background - Hemostemix is an autologous stem cell therapy platform company, recognized for its development of VesCell™ (ACP-01), which has shown promising results in clinical studies for various cardiovascular diseases [9] - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 [9]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies [5] - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide superior clinical benefits [5] - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading statements [5]

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced the closing of its previously announced registered direct offering priced at the market under Nasdaq rules fo ...

MLTX DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 26, 2025 3:10 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and Sep ...